# A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

> **NCT06501534** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** IBI128

## Key facts

- **NCT ID:** NCT06501534
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-10
- **Primary completion:** 2024-12-13
- **Final completion:** 2025-01-09
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501534, "A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06501534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*